The clinical trial aimed to evaluate sodium phenylbutyrate as a potential treatment for pediatric patients with Type II/III Spinal Muscular Atrophy (SMA). Despite the promising mechanism of action related to increasing SMN protein levels, the trial was terminated due to poor compliance with drug administration. This raises concerns regarding patient adherence and the feasibility of future studies. The market for SMA treatments is competitive, with existing therapies such as nusinersen (Spinraza) and onasemnogene abeparvovec (Zolgensma) already established. Any future development of sodium phenylbutyrate would require robust patient engagement strategies and potentially novel delivery mechanisms to ensure compliance. The trial's termination may impact investor confidence and funding opportunities for further research in this area.